Cost/benefit analysis of chlorhexidine-silver sulfadiazine-impregnated venous catheters for femoral access.
Sixty-four patients with chlorhexidine-silver sulfadiazine-impregnated catheters had a lower rate of catheter-related bloodstream infection and lower central venous catheter-related costs per catheter day than 190 patients with a standard catheter.